share_log

港股异动 | 昭衍新药(06127.HK)跌超6%领跌CRO概念 美联储加息可能性仍存 国内创新药仍处调整周期

Changes in Hong Kong stocks | Zhaoyan Pharmaceutical (06127.HK) fell more than 6%, leading the CRO concept, the possibility that the Federal Reserve will raise interest rates is still possible, and domestic innovative drugs are still in the adjustment cyc

Zhitong Finance ·  Apr 16 14:52
CRO concept stocks continued to decline. As of press release, Zhaoyan Pharmaceutical (06127.HK) fell 5.98% to HK$9.28; Tiger Pharmaceuticals (03347.HK) fell 5.93% to HK$30.15; Kanglong Chemical (03759.HK) fell 5.18% to HK$8.78; and Pharmaceuticals (02359.HK) fell 3.96% to HK$32.75.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment